In vivo efficacy of vorinostat and dexamethasone against ALL-2
| . | Median EFS with range, d . | LGD, d . | Log rank value vs control . |
|---|---|---|---|
| Control | 22.4 (17.8-23.0) | ||
| Vorinostat | 23.5 (20.2-35.0) | 1.1 | 0.18 |
| Dexamethasone | 31.5 (20.7-30.4) | 9.1 | 0.012 |
| Vorinostat + dexamethasone | 46.9 (30.0-50.9) | 24.5 | 0.0006 |
| . | Median EFS with range, d . | LGD, d . | Log rank value vs control . |
|---|---|---|---|
| Control | 22.4 (17.8-23.0) | ||
| Vorinostat | 23.5 (20.2-35.0) | 1.1 | 0.18 |
| Dexamethasone | 31.5 (20.7-30.4) | 9.1 | 0.012 |
| Vorinostat + dexamethasone | 46.9 (30.0-50.9) | 24.5 | 0.0006 |
ALL indicates acute lymphoblastic leukemia.